GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Deferred Tax

BridgeBio Pharma (FRA:2CL) Deferred Tax : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

BridgeBio Pharma's change in deferred tax for the three months ended in Mar. 2024 was €0.0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

BridgeBio Pharma Deferred Tax Historical Data

The historical data trend for BridgeBio Pharma's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Deferred Tax Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial - - - - -

BridgeBio Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BridgeBio Pharma Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma Deferred Tax Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (FRA:2CL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Deferred Tax
Comparable Companies
CERE MRTX PCVX HALO ACAD IMVT IMGN INSM ASND BPMC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BBIO:USA
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
Website
https://www.bridgebio.com
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma (FRA:2CL) Headlines

No Headlines